Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs

Biogen's diranersen Phase 2 study showed tau reduction in Alzheimer's but confused experts: The lowest doses had the best results, spurring debate among scientists and rivals.

Raccontata daendpoints.news